Skip to main content
. 2008 May 12;205(5):1155–1171. doi: 10.1084/jem.20072509

Figure 1.

Figure 1.

SEMA3B is significantly expressed in human cancers. (A) SEMA3B expression levels were measured by real-time PCR in 26 different human tumor cell lines, including colorectal carcinomas (HT-29, LoVo, SV80, HCT 116, and Difi), breast adenocarcinomas (SK-BR3, MDA-MB231, and T47D), osteosarcoma cells (U2OS, KHOS-NP, Saos-2, and MG-63), prostate adenocarcinomas (PC-3 and DU145), and melanomas (Sk-Mel-2, UACC-257, MALME-3M, and MDA-MB435; reference 20), as well as gastric carcinoma (GTL-16), hepatocellular carcinoma (HepG2), cervical adenocarcinoma (HeLa), chronic myelogenous leukemia (K-562), pancreatic cancer (SUIT-2), histiocytic lymphoma (U-937), neuroblastoma (IMR5), and nonsmall-cell lung carcinoma (A549). A Taqman probe for human β-actin was used as the internal control for each sample. SEMA3B expression levels in cancer cells were then normalized to the mean (REF = 1; dashed line) of values obtained in three different nontumor immortalized cell lines (mammary epithelial cells [MCF-10A], mesothelial cells [Met-5A], and retinal pigmented epithelium [RPE]). Data are reported as the mean ± SD of triplicates. The y axis is broken to include representation of high value data points. (B) SEMA3B expression in 45 individual samples of malignant melanoma and 18 samples of benign nevi. Reported values indicate normalized SEMA3B detection signals derived from a microarray dataset previously described by Talantov et al. (reference 18). The dashed line indicates the threshold of detection call. None of the nonmalignant samples expressed SEMA3B above the detection confidence threshold, whereas semaphorin expression is high in most melanoma samples (P = 2.5 × 10−11).